Evidence map›Paper›PMID 25410860›Full record

ArticleJournal of virology2015

A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.

Mariana Baz, Myeisha Paskel, Yumiko Matsuoka, James Zengel, Xing Cheng, John J Treanor, Hong Jin, Kanta Subbarao

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in immunology · 2023
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Mariana BazLaboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.
Myeisha PaskelLaboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.
Yumiko MatsuokaLaboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.
James ZengelMedImmune LLC, Mountain View, California, USA.
Xing ChengMedImmune LLC, Mountain View, California, USA.
John J TreanorDepartment of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Hong JinMedImmune LLC, Mountain View, California, USA.
Kanta SubbaraoLaboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA ksubbarao@niaid.nih.gov.
Serimmune (United States) · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USUniversity of Rochester Medical Center · US

Funding

Preclinical Studies of Vaccines for Pandemic InfluenzaZIAAI000933 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SUBBARAO, KANTA · 2009 to 2017
$13.7M
Intramural NIH HHS
6 · The paper itself

Abstract

unlabelledEquine influenza viruses (EIV) are responsible for rapidly spreading outbreaks of respiratory disease in horses. Although natural infections of humans with EIV have not been reported, experimental inoculation of humans with these viruses can lead to a productive infection and elicit a neutralizing antibody response. Moreover, EIV have crossed the species barrier to infect dogs, pigs, and camels and therefore may also pose a threat to humans. Based on serologic cross-reactivity of H3N8 EIV from different lineages and sublineages, A/equine/Georgia/1/1981 (eq/GA/81) was selected to produce a live attenuated candidate vaccine by reverse genetics with the hemagglutinin and neuraminidase genes of the eq/GA/81 wild-type (wt) virus and the six internal protein genes of the cold-adapted (ca) A/Ann Arbor/6/60 (H2N2) vaccine donor virus, which is the backbone of the licensed seasonal live attenuated influenza vaccine. In both mice and ferrets, intranasal administration of a single dose of the eq/GA/81 ca vaccine virus induced neutralizing antibodies and conferred complete protection from homologous wt virus challenge in the upper respiratory tract. One dose of the eq/GA/81 ca vaccine also induced neutralizing antibodies and conferred complete protection in mice and nearly complete protection in ferrets upon heterologous challenge with the H3N8 (eq/Newmarket/03) wt virus. These data support further evaluation of the eq/GA/81 ca vaccine in humans for use in the event of transmission of an equine H3N8 influenza virus to humans. IMPORTANCE: Equine influenza viruses have crossed the species barrier to infect other mammals such as dogs, pigs, and camels and therefore may also pose a threat to humans. We believe that it is important to develop vaccines against equine influenza viruses in the event that an EIV evolves, adapts, and spreads in humans, causing disease. We generated a live attenuated H3N8 vaccine candidate and demonstrated that the vaccine was immunogenic and protected mice and ferrets against homologous and heterologous EIV.

Indexed as

Administration, IntranasalAnimalsAntibodies, NeutralizingAntibodies, ViralCross ProtectionCross ReactionsDisease Models, AnimalFerretsInfluenza A Virus, H3N8 SubtypeInfluenza VaccinesMice, Inbred BALB COrthomyxoviridae InfectionsVaccines, AttenuatedAntibodies, NeutralizingAntibodies, ViralInfluenza VaccinesVaccines, Attenuated

Identifiers

PMID25410860
PMCPMC4300743
OpenAlexW2026820320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.